Edwards Lifesciences Reports Strong Q4 2025 Earnings, Projects Confident 2026 Outlook

Edwards Lifesciences Corp (EW) reported robust financial results for the fourth quarter of 2025, with sales increasing by 11.6%. This strong quarterly performance contributed to an impressive 10.7% full-year sales growth, primarily driven by the strong performance of its TAVR and TMTT segments. The company attributed its success to strategic investments and the exploration of future growth opportunities. Looking ahead, Edwards Lifesciences maintains a positive outlook and has issued confident sales and EPS guidance for 2026. This strong trajectory underscores the company's healthy financial position and potential for sustained investor interest.